The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called TransCon IL-2 beta/gamma when given in combination with chemotherapy or in combination with another experimental drug, TransCon TLR7/8 Agonist, for the treatment of advanced cancer. Specifically, researchers aim to determine whether the addition of TransCon IL-2 beta/gamma or TransCon TLR7/8 Agonist leads to better outcomes for patients with platinum-resistant ovarian cancer or recurrent/metastatic (cancer that has spread to other parts of the body) cervical cancer. Researchers will also examine the effect of the drugs on the patient's cancer by conducting biomarker studies. Biomarkers are important biological indicators that can be measured from blood and tumor tissues.
What is the full name of this clinical trial?
ASND0029 IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 beta/gamma Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies
Rimel, Bobbie Jo
Andrew Li, Kamya Sankar, Kenneth Kim, Kristin Taylor, Margaret Liang